[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.191.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
February 14, 2019

Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors

Author Affiliations
  • 1Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
  • 2Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy
JAMA Oncol. 2019;5(4):489-490. doi:10.1001/jamaoncol.2018.6694

In recent years, the number of treatments for metastatic, well-differentiated gastrointestinal and pancreatic neuroendocrine tumors (NETs) has expanded significantly.1 New medications for tumor control as well as symptom control include somatostatin analogues, everolimus, sunitinib, telotristat, and lutetium Lu 177 (177Lu)-dotatate. These new therapies have been approved based on randomized clinical trials—an effort that has required international cooperation given the relative scarcity of metastatic NETs.

×